Skip to main content
SpringerLink
Log in

Formulation of Osimertinib Nano Lipid Carriers: Optimization, Characterization and Cytotoxicity Assessment

  • Original Paper
  • Published:
Journal of Cluster Science Aims and scope Submit manuscript

Abstract

In the present study, orally administered Osimertinib nanostructured lipid carriers (OSM-NLCs) was prepared by the hot-melt emulsification and sonication method. The formulations were optimized by Box-Behnken design to get the optimum composition. The optimized formulation (OSM-NLCop) was further evaluated for in-vitro, ex-vivo parameters as well as in-vitro cytotoxicity evaluation against lung cancer cell line. The selected OSM-NLCop has shown a particle size of 162.6 ± 3.5 nm, PDI 0.25, entrapment efficiency 80.2 ± 3.9% with the negative zeta potential (− 24.7 mV). OSM-NLCop showed significant (p < 0.05) high drug release (82.52 ± 5.4%) as compared to pure OSM (24.7 ± 3.6%). Drug release profile from OSM-NLCop displayed Fickian release kinetic with Korsmeyer-Peppas release model. It also exhibited significantly high permeation with 4.8-fold enhancement in the permeation flux than pure OSM dispersion. OSM-NLCs also depicted (p < 0.05) lesser cytotoxicity against the tested lung cancer cell and reduced IC50 value as compared to pure OSM. From the findings, it can be concluded that NLCs are promising carriers for the delivery of OSM and may improve the therapeutic efficacy against lung cancer cell lines.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3.
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8

Similar content being viewed by others

References

  1. R. L. Siegel, K. D. Miller, and A. Jemal (2018). Cancer statistics, 2018. CA: Cancer J. Clin. 68, 7–30.

    PubMed  Google Scholar 

  2. J. Zhu, Y. Huang, J. Zhang, Y. Feng, and L. Shen (2020). Formulation, preparation and evaluation of nanostructured lipid carrier containing naringin and coix seed oil for anti-tumor application based on “unification of medicines and excipients.” Drug Des Devel Ther. 14, 1481–1491.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. P. Zhou, G. Chen, M. Gao, and J. Wu (2018). Design, synthesis and evaluation of the osimertinib analogue (C-005) as potent EGFR inhibitor against NSCLC. Bioorgan. Med. Chem. 26 (23–24), 6135–6145.

    Article  CAS  Google Scholar 

  4. S. S. Ramalingam, J. Vansteenkiste, D. Planchard, B. C. Cho, J. E. Gray, Y. Ohe, C. Zhou, T. Reungwetwattana, Y. Cheng, B. Chewaskulyong, R. Shah, M. Cobo, K. H. Lee, P. Cheema, M. Tiseo, T. John, M. C. Lin, F. Imamura, T. Kurata, A. Todd, R. Hodge, M. Saggese, Y. Rukazenkov, and J. C. Soria (2020). Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N. Engl. J. Med. 382, 41–50.

    Article  CAS  PubMed  Google Scholar 

  5. N. Kommineni, E. Nottingham, A. Bagde, N. Patel, A. Rishi, S. R. S. Dev, and M. Singh (2021). Role of nano-lipid formulation of CARP-1 mimetic, CFM-4.17 to improve systemic exposure and response in osimertinib resistant non-small cell lung cancer. Eur J Pharm Biopharm. 158, 172–184.

    Article  CAS  PubMed  Google Scholar 

  6. S. S. Sawant, S. M. Patil, S. K. Shukla, N. S. Kulkarni, V. Gupta, and N. K. Kunda (2021). Pulmonary delivery of osimertinib liposomes for non-small cell lung cancer treatment: formulation development and in vitro evaluation. Drug Deliv and Transl Res. https://doi.org/10.1007/s13346-021-01088-0.

    Article  Google Scholar 

  7. M. K. Anwer, M. M. Ahmed, F. Fatima, S. M. Alshahrani, M. F. Aldawsari, A. Alalaiwe, R. Al-Shdefat, and F. Shakeel (2019). Solubility, solution thermodynamics and molecular interactions of osimertinib in some pharmaceutically useful solvents. J. Mol. Liq 284, 53–58.

    Article  CAS  Google Scholar 

  8. M. M. Ahmed, F. Fatima, M. K. Anwer, M. F. Aldawsari, B. K. Almutairy, S. M. Alshahrani, M. Iqbal, S. Bhatia, and A. Z. Alanazi (2020). Development and characterization of osimertinib loaded ethylcellulose based sustained release nanosponges: cytotoxicity and biocompatibility studies. Lat. Am. J. Pharm. 39 (7), 1292–1299.

    CAS  Google Scholar 

  9. P. Skupin-Mrugalska and T. Minko (2020). Development of liposomal vesicles for osimertinib delivery to EGFR mutation-positive lung cancer cells. Pharmaceutics. 12 (10), 939.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. X. Hu, S. Chen, H. Yin, Q. Wang, Y. Duan, L. Jiang, and L. Zhao (2020). Chitooligosaccharides-modified PLGA nanoparticles enhance the antitumor efficacy of AZD9291 (Osimertinib) by promoting apoptosis. Int. J. Biol. Macromol. 162, 262–272.

    Article  CAS  PubMed  Google Scholar 

  11. M. H. Kim, K. T. Kim, S. Y. Sohn, J. Y. Lee, C. H. Lee, H. Yang, B. K. Lee, K. W. Lee, and D. D. Kim (2019). Formulation and evaluation of nanostructured lipid carriers (NLCs) Of 20(S)-protopanaxadiol (PPD) by box-behnken design. Int. J. Nanomed. 14, 8509–8520.

    Article  CAS  Google Scholar 

  12. T. Ai, W. Shang, H. Yan, C. Zeng, K. Wang, Y. Gao, T. Guan, C. Fang, and J. Tian (2018). Near infrared-emitting persistent luminescent nanoparticles for hepatocellular carcinoma imaging and luminescence-guided surgery. Biomaterials. 167, 216–225.

    Article  CAS  PubMed  Google Scholar 

  13. K. C. Bentz and D. A. Savin (2018). Hollow polymer nanocapsules: synthesis, properties, and applications. Polym. Chem. 9, 2059–2081.

    Article  CAS  Google Scholar 

  14. C. Thapa, A. Ahad, M. Aqil, S. S. Imam, and Y. Sultana (2018). Formulation and optimization of nanostructured lipid carriers to enhance oral bioavailability of telmisartan using Box-Behnken design. J. Drug Del. Sci. Tech. 44, 431–439.

    Article  CAS  Google Scholar 

  15. R. H. Muller, M. Radtke, and S. A. Wissing (2002). Solid lipid nanoparticles (sln) and nanostructured lipid carriers (nlc) in cosmetic and dermatological preparations. Adv. Drug Deliv. Rev. 54 (Suppl 1), S131-155.

    Article  CAS  PubMed  Google Scholar 

  16. S. M. Moghddam, A. Ahad, M. Aqil, S. S. Imam, and Y. Sultana (2016). Optimization of nanostructured lipid carriers for topical delivery of nimesulide using box-behnken design approach. Artif. Cells Nanomed. Biotechnol. 45(3), 617–624.

  17. E. B. Souto, S. A. Wissing, C. M. Barbosa, and R. H. Muller (2004). Development of a controlled release formulation based on sln and nlc for topical clotrimazole delivery. Int. J. Pharm. 278, 71–77.

    Article  CAS  PubMed  Google Scholar 

  18. V. Jenning, A. F. Thunemann, and S. H. Gohla (2000). Characterisation of a novel solid lipid nanoparticle carrier system based on binary mixtures of liquid and solid lipids. Int. J. Pharm. 199, 167–177.

    Article  CAS  PubMed  Google Scholar 

  19. C. Y. Chen, Y. H. Lee, S. H. Chang, Y. F. Tsai, J. Y. Fang, and T. L. Hwang (2019). Oleic acid-loaded nanostructured lipid carrier inhibit neutrophil activities in the presence of albumin and alleviates skin inflammation. Int. J. Nanomed. 14, 6539–6553.

    Article  CAS  Google Scholar 

  20. O. A. A. Ahmed, U. A. Fahmy, R. Bakhaidar, et al. (2020). Pumpkin oil-based nanostructured lipid carrier system for antiulcer effect in NSAID-induced gastric ulcer model in rats. Int. J. Nanomed. 15, 2529–2539.

    Article  CAS  Google Scholar 

  21. G. Shevalkar, M. Pawar, and P. Vavia (2021). Nanostructured lipid carriers (NLCs) of lumefantrine with enhanced permeation. J Pharm Innov. https://doi.org/10.1007/s12247-021-09590-1.

    Article  Google Scholar 

  22. X. Peng, G. Yang, Y. Shi, et al. (2020). Box-Behnken design based statistical modeling for the extraction and physicochemical properties of pectin from sunflower heads and the comparison with commercial low-methoxyl pectin. Sci. Rep. 10, 3595.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. A. Kumar, A. Singh, S. J. S. Flora, and R. Shukla (2021). Box-behnken design optimized TPGS coated bovine serum albumin nanoparticles loaded with anastrozole. Curr. Drug Deliv. 18 (8), 1136–1147.

    Article  PubMed  Google Scholar 

  24. D. Parashar, N. P. Aditya, and R. S. R. Murthy (2016). Development of artemether and lumefantrine co-loaded nanostructured lipid carriers: physicochemical characterization and in vivo antimalarial activity. Drug Deliv. 23, 123–129.

    Article  CAS  PubMed  Google Scholar 

  25. M. N. Saleem and M. Idris M (2016). Formulation design and development of a unani transdermal patch for antiemetic therapy and its pharmaceutical evaluation. Scientifica Article ID 7602347.

  26. J. M. Haigh and E. W. Smith (1994). The selection and use of natural and synthetic membranes for in vitro diffusion experiments. Eur J. Pharm. Sci. 2 (5–6), 311–330.

    Article  CAS  Google Scholar 

  27. M. J. Ansari and S. M. Alshahrani (2021). Solubility determination of osimertinib mesylate in various solvents by validated, rapid, highly sensitive, water rich reverse phase high-performance liquid chromatography. Lat. Am. J. Pharm. 40 (5), 1084–1093.

    CAS  Google Scholar 

  28. T. Mosmann (1983). Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J. Imm Meth. 65, 55–63.

    Article  CAS  Google Scholar 

  29. L. Tolosa, M. T. Donato, and M. J. Gómez-Lechón (2014). General cytotoxicity assessment by means of the MTT assay. Protocols in In Vitro Hepatocyte Res 333–348.

  30. I. Jazuli, B. Nabi, T. Moolakkadath, T. Alam, S. Baboota, and J. Ali (2019). Optimization of nanostructured lipid carriers of lurasidone hydrochloride using box-behnken design for brain targeting: in vitro and in vivo studies. J. Pharm. Sci. 108, 3082–3090.

    Article  CAS  PubMed  Google Scholar 

  31. T. Alam, S. Khan, B. Gaba, F. Haider, S. Baboota, and J. Ali (2018). Adaptation of quality by design-based development of isradipine nanostructured-lipid carrier and its evaluation for in vitro gut permeation and in vivo solubilization fate. J. Pharm. Sci. 107 (11), 2914–2926.

    Article  CAS  PubMed  Google Scholar 

  32. N. Rangaraj, S. R. Pailla, S. Shah, S. Prajapati, and S. Sampathi (2020). QbD aided development of ibrutinib-loaded nanostructured lipid carriers aimed for lymphatic targeting: evaluation using chylomicron flow blocking approach. Drug Del. Trans. Res. 10, 1476–1494.

    Article  CAS  Google Scholar 

  33. S. Uprit, R. Kumar Sahu, A. Roy, et al. (2013). Preparation and characterization of minoxidil loaded nanostructured lipid carrier gel for effective treatment of alopecia. Saudi Pharm J. 21 (4), 379–385.

    Article  PubMed  PubMed Central  Google Scholar 

  34. M. Elmowafy, H. M. Ibrahim, M. A. Ahmed, K. Shalaby, A. Salama, and H. Hefesha (2017). Atorvastatin-loaded nanostructured lipid carriers (NLCs): strategy to overcome oral delivery drawbacks. Drug Deliv. 24 (1), 932–941.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  35. R. S. Rabelo, I. F. Oliveira, V. M. da Silva, A. S. Prata, and M. D. Hubinger (2018). Chitosan coated nanostructured lipid carriers (NLCs) for loading Vitamin D: a physical stability study. Int. J. Biol. Macromol. 119, 902–912.

    Article  CAS  PubMed  Google Scholar 

  36. M. Danaei, M. Dehghankhold, S. Ataei, D. F. Hasanzadeh, R. Javanmard, A. Dokhani, S. Khorasani, and M. R. Mozafari (2018). Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 10 (2), 57.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Joseph E, Singhvi G (2019) Multifunctional nanocrystals for cancer therapy: a potential nanocarrier. Nanomat. Drug Del. Ther. 91–116

  38. P. W. Dhore, V. S. Dave, S. D. Saoji, Y. S. Bobde, C. Mack, and N. A. Raut (2017). Enhancement of the aqueous solubility and permeability of a poorly water soluble drug ritonavir via lyophilized milk-based solid dispersions. Pharm. Dev. Technol. 22 (1), 90–102.

    Article  CAS  PubMed  Google Scholar 

  39. W. Wu, Y. Zu, L. Wang, L. Wang, H. Wang, Y. Li, M. Wu, X. Zhao, and Y. Fu (2017). Preparation, characterization and antitumor activity evaluation of apigenin nanoparticles by the liquid antisolvent precipitation technique. Drug Del. 24 (1), 1713–1720.

    Article  CAS  Google Scholar 

  40. S. Shanmugam, C. K. Song, S. N. Sriraman, R. Baskaran, C. S. Yong, H. G. Choi, D. D. Kim, J. S. Woo, and B. K. Yoo (2009). Physicochemical characterization and skin permeation of liposome formulations containing clindamycin phosphate. Arch Pharm. Res. 32 (7), 1067–1075.

    Article  CAS  PubMed  Google Scholar 

  41. Y. Neupane, M. Srivastava, N. Ahmad, N. Kumar, A. Bhatnagar, and K. Kohli (2014). Lipid based nanocarrier system for the potential oral delivery of decitabine: Formulation design, characterization, ex vivo, and in vivo assessment. Int. J. Pharm. 477 (1–2), 601–612.

    Article  CAS  PubMed  Google Scholar 

  42. A. Khosa, S. Reddi, and R. N. Sahab (2018). Nanostructured lipid carriers for site-specific drug delivery. Biomed. Pharmacother. 103, 598–613.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgement

This research project is supported by Princess Nourah bint Abdulrahman University Researcher Supporting Project number (PNURSP2022R108), Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia for supporting this project.

Funding

Authors are thankful to Princess Nourah bint Abdulrahman University Researcher Supporting Project Number (PNURSP2022R108), Princess Nourah bint Abdulrahman University, Riyadh, Saudi Arabia for funding this research work.

Author information

Authors and Affiliations

  1. Department of Basic Health Sciences, Preparatory Year, Princess Nourah Bint Abdulrahman University, Riyadh, 11671, Saudi Arabia

    Sadaf Jamal Gilani

  2. Biology Department, College of Science, Princess Nourah Bint Abdulrahman University, Riyadh, 11671, Saudi Arabia

    May Nasser Bin-Jumah

  3. Environment and Biomaterial Unit, Health Sciences Research Center, Princess Nourah Bint Abdulrahman University, Riyadh, 11671, Saudi Arabia

    May Nasser Bin-Jumah

  4. Department of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh, 11451, Saudi Arabia

    Syed Sarim Imam & Sultan Alshehri

  5. Department of Pharmaceutics, College of Pharmacy, Jouf University, Sakaka, 72341, Aljouf, Saudi Arabia

    Ameeduzzafar Zafar

  6. Department of Pharmacy, College of Health Science, Arsi University, Asella, Ethiopia

    Mohd Yasir

  7. Department of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Ad Diriyah, 13713, Saudi Arabia

    Muhammed M. Ghuneim

Authors
  1. Sadaf Jamal Gilani
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. May Nasser Bin-Jumah
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Syed Sarim Imam
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ameeduzzafar Zafar
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Mohd Yasir
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Sultan Alshehri
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Muhammed M. Ghuneim
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Syed Sarim Imam.

Ethics declarations

Conflict of interest

The author declare that they have no conflict of interest.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Gilani, S.J., Bin-Jumah, M.N., Imam, S.S. et al. Formulation of Osimertinib Nano Lipid Carriers: Optimization, Characterization and Cytotoxicity Assessment. J Clust Sci 34, 1051–1063 (2023). https://doi.org/10.1007/s10876-022-02282-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10876-022-02282-x

Keywords

Search

Navigation